-
Something wrong with this record ?
Functional characterization and immunogenicity of a novel vaccine candidate against tick-borne encephalitis virus based on Leishmania-derived virus-like particles
M. Zimna, G. Brzuska, J. Salát, P. Svoboda, K. Baranska, B. Szewczyk, D. Růžek, E. Krol
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Encephalitis, Tick-Borne * prevention & control MeSH
- Leishmania * MeSH
- Humans MeSH
- Mice MeSH
- Antibodies, Neutralizing MeSH
- Sheep MeSH
- Antibodies, Viral MeSH
- Cattle MeSH
- Viral Vaccines * MeSH
- Encephalitis Viruses, Tick-Borne * genetics MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Cattle MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Tick-borne encephalitis virus (TBEV) is a major cause of neurological infections in many regions of central, eastern and northern Europe and northern Asia. In approximately 15% of cases, TBEV infections lead to the development of severe encephalitis or meningitis. The main route of TBEV transmission is tick bites; however, ingestion of dairy products from infected animals (goats, cattle and sheep) is also a frequent cause of the disease. Therefore, vaccination of livestock in virus endemic regions could also contribute to the decrease in TBEV infection among humans. Although few vaccines against TBEV based on inactivated viruses are available for humans, due to high costs, vaccination is not mandatory in most of the affected countries. Moreover, there is still no vaccine for veterinary use. Here, we present a characterization and immunogenicity study of a new potential TBEV vaccine based on virus-like particles (VLPs) produced in Leishmania tarentolae cells. VLPs, which mimic native viral particles but do not contain genetic material, show good immunogenic potential. For the first time, we showed that the protozoan L. tarentolae expression system can be successfully used for the production of TBEV virus-like particles with highly efficient production. We confirmed that TBEV recombinant structural proteins (prM/M and E) from VLPs are highly recognized by neutralizing antibodies in in vitro analyses. Therefore, VLPs in combination with AddaVax adjuvant were used in immunization studies in a mouse model. VLPs proved to be highly immunogenic and induced the production of high levels of neutralizing antibodies. In a challenge experiment, immunization with VLPs provided full protection from lethal TBE in mice. Thus, we suggest that Leishmania-derived VLPs may be a good candidate for a safe alternative human vaccine with high efficiency of production. Moreover, this potential vaccine candidate may constitute a low-cost candidate for veterinary use.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004719
- 003
- CZ-PrNML
- 005
- 20230808104549.0
- 007
- ta
- 008
- 230418s2023 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.antiviral.2022.105511 $2 doi
- 035 __
- $a (PubMed)36581050
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Zimna, Marta $u Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland. Electronic address: marta.zimna@phdstud.ug.edu.pl
- 245 10
- $a Functional characterization and immunogenicity of a novel vaccine candidate against tick-borne encephalitis virus based on Leishmania-derived virus-like particles / $c M. Zimna, G. Brzuska, J. Salát, P. Svoboda, K. Baranska, B. Szewczyk, D. Růžek, E. Krol
- 520 9_
- $a Tick-borne encephalitis virus (TBEV) is a major cause of neurological infections in many regions of central, eastern and northern Europe and northern Asia. In approximately 15% of cases, TBEV infections lead to the development of severe encephalitis or meningitis. The main route of TBEV transmission is tick bites; however, ingestion of dairy products from infected animals (goats, cattle and sheep) is also a frequent cause of the disease. Therefore, vaccination of livestock in virus endemic regions could also contribute to the decrease in TBEV infection among humans. Although few vaccines against TBEV based on inactivated viruses are available for humans, due to high costs, vaccination is not mandatory in most of the affected countries. Moreover, there is still no vaccine for veterinary use. Here, we present a characterization and immunogenicity study of a new potential TBEV vaccine based on virus-like particles (VLPs) produced in Leishmania tarentolae cells. VLPs, which mimic native viral particles but do not contain genetic material, show good immunogenic potential. For the first time, we showed that the protozoan L. tarentolae expression system can be successfully used for the production of TBEV virus-like particles with highly efficient production. We confirmed that TBEV recombinant structural proteins (prM/M and E) from VLPs are highly recognized by neutralizing antibodies in in vitro analyses. Therefore, VLPs in combination with AddaVax adjuvant were used in immunization studies in a mouse model. VLPs proved to be highly immunogenic and induced the production of high levels of neutralizing antibodies. In a challenge experiment, immunization with VLPs provided full protection from lethal TBE in mice. Thus, we suggest that Leishmania-derived VLPs may be a good candidate for a safe alternative human vaccine with high efficiency of production. Moreover, this potential vaccine candidate may constitute a low-cost candidate for veterinary use.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a ovce $7 D012756
- 650 _2
- $a skot $7 D002417
- 650 _2
- $a protilátky virové $7 D000914
- 650 12
- $a viry klíšťové encefalitidy $x genetika $7 D004669
- 650 12
- $a virové vakcíny $7 D014765
- 650 12
- $a Leishmania $7 D007891
- 650 12
- $a klíšťová encefalitida $x prevence a kontrola $7 D004675
- 650 _2
- $a neutralizující protilátky $7 D057134
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Brzuska, Gabriela $u Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland. Electronic address: gabriela.brzuska@phdstud.ug.edu.pl
- 700 1_
- $a Salát, Jiří $u Laboratory of Emerging Viral Infections, Veterinary Research Institute, Hudcova 70, CZ, 62100, Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ, 37005, Ceske Budejovice, Czech Republic. Electronic address: salat@vri.cz
- 700 1_
- $a Svoboda, Pavel $u Laboratory of Emerging Viral Infections, Veterinary Research Institute, Hudcova 70, CZ, 62100, Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ, 37005, Ceske Budejovice, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 735/5, CZ, 62500, Brno, Czech Republic; Faculty of Veterinary Medicine, University of Veterinary Sciences Brno, Palackeho Tr. 1946/1, 61242, Brno, Czech Republic. Electronic address: svoboda@vri.cz
- 700 1_
- $a Baranska, Klaudia $u Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland. Electronic address: klaudia.baranska@phdstud.ug.edu.pl
- 700 1_
- $a Szewczyk, Boguslaw $u Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland. Electronic address: boguslaw.szewczyk@biotech.ug.edu.pl
- 700 1_
- $a Růžek, Daniel, $u Laboratory of Emerging Viral Infections, Veterinary Research Institute, Hudcova 70, CZ, 62100, Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ, 37005, Ceske Budejovice, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 735/5, CZ, 62500, Brno, Czech Republic. Electronic address: ruzekd@paru.cas.cz $d 1981- $7 stk2008441707
- 700 1_
- $a Krol, Ewelina $u Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland. Electronic address: ewelina.krol@biotech.ug.edu.pl
- 773 0_
- $w MED00000480 $t Antiviral research $x 1872-9096 $g Roč. 209, č. - (2023), s. 105511
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36581050 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230808104546 $b ABA008
- 999 __
- $a ok $b bmc $g 1925044 $s 1190928
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 209 $c - $d 105511 $e 20221227 $i 1872-9096 $m Antiviral research $n Antiviral Res $x MED00000480
- LZP __
- $a Pubmed-20230418